DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lkjmh2/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- CymaBay Therapeutics, Inc.
- Kissei Pharmaceutical Co., Ltd.
- LG Life Sciences, Ltd.
- Nippon Chemiphar Co., Ltd.
- Polaris Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Limited
Drug Profiles
- arhalofenate
- febuxostat
- febuxostat XR
- JPH-367
- KGO-2142
- KGO-2173
- KUX-1151
- LC-350189
- NC-2500
- pegadricase
- RDEA-3170
- Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia
- Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia
- XEN-102
For more information visit http://www.researchandmarkets.com/research/lkjmh2/hyperuricemia